TY - JOUR
T1 - COVID-19 in patients with neuroendocrine neoplasms
T2 - 2-year results of the INTENSIVE study
AU - Fazio, Nicola
AU - Gervaso, Lorenzo
AU - Halfdanarson, Thorvardur R.
AU - Sonbol, Mohamad
AU - Eiring, Rachel A.
AU - Pusceddu, Sara
AU - Prinzi, Natalie
AU - Stocchetti, Benedetta Lombardi
AU - Grozinsky-Glasberg, Simona
AU - Gross, David J.
AU - Walter, Thomas
AU - Robelin, Patrick
AU - Lombard-Bohas, Catherine
AU - Frassoni, Samuele
AU - Bagnardi, Vincenzo
AU - Antonuzzo, Lorenzo
AU - Sparano, Clotilde
AU - Massironi, Sara
AU - Gelsomino, Fabio
AU - Bongiovanni, Alberto
AU - Ranallo, Nicoletta
AU - Tafuto, Salvatore
AU - Rossi, Maura
AU - Cives, Mauro
AU - Kakil, Ibrahim Rasul
AU - Hamid, Hytam
AU - Chirco, Alessandra
AU - Squadroni, Michela
AU - Salvia, Anna La
AU - Hernando, Jorge
AU - Hofland, Johannes
AU - Koumarianou, Anna
AU - Boselli, Sabrina
AU - Tamayo, Darina
AU - Mazzon, Cristina
AU - Rubino, Manila
AU - Spada, Francesca
N1 - Publisher Copyright:
© 2023 the author(s) Published by Bioscientifica Ltd. Printed in Great Britain.
PY - 2023/6
Y1 - 2023/6
N2 - We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
AB - We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
UR - http://www.scopus.com/inward/record.url?scp=85160223514&partnerID=8YFLogxK
U2 - 10.1530/erc-22-0395
DO - 10.1530/erc-22-0395
M3 - Article
C2 - 36930250
AN - SCOPUS:85160223514
SN - 1351-0088
VL - 30
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 6
M1 - e220395
ER -
